The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
The UK has the world's highest death rate for COVID this week with 71 deaths per million population our nearest rivals are Italy and Russia who each have less than half our death rate. This world beating data doesn't even make the news if COVID free Britain. Meantime our world beating government stops testing.
Future focus on high-margin in vitro diagnostics (IVDs): Novacyt is looking to drive further revenue growth and profitability via an increased focus on clinical IVD products rather than the traditional offering of research use only (RUO) and industrial tests. These IVD products should offer higher margins than RUOs and generate higher profitability for the Group in the long-term.
Outlook: Through the rapid commercialisation of a COVID-19 test, Novacyt has transformed its financial position. Demand for the Group’s COVID-19 test and other COVID-19 reagents are expected to make up the majority of revenue generated until FY22E, whereupon the Group is looking to drive long-term growth across its business via the development of high-margin clinical diagnostics and establish itself as a leader in infectious disease testing. A significant cash position estimated to be €409.3m by the end of FY22E should provide Novacyt with a financial platform to create further value. We initiate coverage with a BUY rating and a 1,463p price target.
Sir Kier Starmers wife is a NHS doctor actively treating Covid cases. What crass sentiments expressed on this site. I am here because I have invested in a great company. Don’t want to hear your political opinions.
I have not posted anything for some time, suffice to say I am fully invested in the company and have not parted with a single share as values fell significantly. Tomorrow shall be the first indication of whether my faith in the company and its products is justified. I am quietly confident.
I am fully invested but wish I had more cash to invest in Novacyt which is a company with ALL the elements in place to make a killing when we start seeing real numbers and not speculation. The contract dispute with the Dept of health is a minor matter that will not influence Pathology managers on whether to buy Novacyt kit or reagents(I say this as a retired pathology lab manager who specialised in PCR). Stay strong, the share will come good as the reagents from Novacyt are still being purchased by the NHS.
Take courage, the company is still good and will progress, too much emphasis put on the DHSC contract with a govt under huge pressure over contracts to the undeserving. Novacyt is an innovator and is still selling into the NHS with or without a DHSC contract plus the non UK government sales are growing. This company has not hired new full time employees without markets to sell into. Courage and even more patience than expected but that is investing, it has its risks but Novacyt at this point is pure gold if you have the cash to delve in.
Wish I had money to buy up more shares at this price. Sounds like contract negotiations are ongoing with the DHSC playing hard ball. They will still be buying but via the NHS where testing is growing as lighthouse labs are packed up. This share will still flourish, quality comes through.
I similarly have recommended the share to my daughter to buy which she has. I would not do that if I was not fairly sure about where the share price sits. Now she has to learn patience to wait out the investment vagaries of the market.
It is now the time where we await the release of activity figures which will come. Evidence is all around that the company is expanding activity the most compelling of which I feel is the expansion of the workforce. We have to sit out the price manipulation of the share with great patience.
Troublesome; track and trace looks like the shambles it has been from the day it was handed to party "chums" to run ignoring the professionals. As Gove says, "who needs experts" Thank goodness Nova is expert in all that it does.
Earth70000, have we become the flat earth society on Covid vaccines. Nova cut is a great company and greatly undervalued. Further to this Covid 19 is a deadly virus for a significant number of fellow citizens and over 120,000 families are grieving their loved ones.
Try2buylow: I hope you are following your name and buying low. The company is in the strong position as a business because of its research arm. It is foolish companies without an eye on the future who simply capitalise on what they have today.. Novacyt is a company for today and tomorrow, they have eliminated debt, established contracts the value of which we wait to hear but I am confident they will not disappoint, and they have a firm eye on the future.
pebble101, not sure what the point of your post was but it read like Covid victims would have died of something else anyway. So I post the following on recent EXCESS deaths to counter the notion Covid is not responsible. These figures are for one week in an improving situation.
“The number of weekly excess deaths recorded in England and Wales was 4,986 for the week ending February 5, 2021, a decrease from the previous week and an indication that the Coronavirus situation in the UK is gradually improving. “ - Source Statistica.
I bought these shares because the company is indicative, profitable and we'll ran with an expanding market. I will hold for the long term because I believe it is a winner and will not let go of my precious shares to market traders. Courage needed to be rewarded.
Hillseeker, although I am not familiar with the test protocol of SNPsig I would be surprised to find that they have not mupliplexed the assay to detect multiple variants in a single PCR reaction. I may have misunderstood you but it sounded as if you suggest they test for individual variants in different test wells. Also what do you mean by a cabinet will be needed?